Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bortezomib + Dexamethasone + LGH447 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bortezomib | Velcade | Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov). | ||
| Dexamethasone | Adexone | Desametasone | ||
| LGH447 | LGB321|PIM447|LGH-447|PIM-447 | PIM Inhibitor (Pan) 10 | LGH447 is a pan-PIM protein kinase inhibitor, which leads to cell cycle arrest and growth inhibition in PIM-expressing tumor cells (PMID: 24474669, PMID: 30370255). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|